[go: up one dir, main page]

HK1249409B - 5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer - Google Patents

5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer Download PDF

Info

Publication number
HK1249409B
HK1249409B HK18108031.4A HK18108031A HK1249409B HK 1249409 B HK1249409 B HK 1249409B HK 18108031 A HK18108031 A HK 18108031A HK 1249409 B HK1249409 B HK 1249409B
Authority
HK
Hong Kong
Prior art keywords
seq
bap049
amino acid
acid sequence
clone
Prior art date
Application number
HK18108031.4A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1249409A1 (en
Inventor
Sanela Bilic
Juan Alberto Camacho Gomez
John Scott CAMERON
Julio Cesar Castro-Palomino Laria
JR. Danny Roland HOWARD
Original Assignee
Novartis Ag
Palobiofarma, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Palobiofarma, S.L. filed Critical Novartis Ag
Priority claimed from PCT/IB2016/054834 external-priority patent/WO2017025918A1/en
Publication of HK1249409A1 publication Critical patent/HK1249409A1/en
Publication of HK1249409B publication Critical patent/HK1249409B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK18108031.4A 2015-08-11 2016-08-10 5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer HK1249409B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15382425.5 2015-08-11
EP15382425 2015-08-11
US201662335984P 2016-05-13 2016-05-13
US62/335,984 2016-05-13
PCT/IB2016/054834 WO2017025918A1 (en) 2015-08-11 2016-08-10 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer

Publications (2)

Publication Number Publication Date
HK1249409A1 HK1249409A1 (en) 2018-11-02
HK1249409B true HK1249409B (en) 2020-05-08

Family

ID=65563017

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18108031.4A HK1249409B (en) 2015-08-11 2016-08-10 5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer

Country Status (13)

Country Link
JP (1) JP6964113B2 (ru)
KR (1) KR102226100B1 (ru)
CL (1) CL2018000349A1 (ru)
DK (1) DK3334431T3 (ru)
ES (1) ES2761910T3 (ru)
HK (1) HK1249409B (ru)
HR (1) HRP20192192T1 (ru)
HU (1) HUE046646T2 (ru)
IL (1) IL257350A (ru)
LT (1) LT3334431T (ru)
PT (1) PT3334431T (ru)
RU (1) RU2745560C2 (ru)
ZA (1) ZA201800792B (ru)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.

Also Published As

Publication number Publication date
DK3334431T3 (da) 2020-01-02
JP2019218346A (ja) 2019-12-26
ES2761910T3 (es) 2020-05-21
ZA201800792B (en) 2019-06-26
KR102226100B1 (ko) 2021-03-10
RU2018108050A (ru) 2019-09-13
PT3334431T (pt) 2020-01-06
JP6964113B2 (ja) 2021-11-10
HUE046646T2 (hu) 2020-03-30
HRP20192192T1 (hr) 2020-03-06
LT3334431T (lt) 2019-12-27
KR20200057790A (ko) 2020-05-26
RU2745560C2 (ru) 2021-03-29
IL257350A (en) 2018-03-29
RU2018108050A3 (ru) 2020-02-17
CL2018000349A1 (es) 2018-09-07

Similar Documents

Publication Publication Date Title
EP3334431B1 (en) 5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer
JP7488323B2 (ja) 抗ｌａｇ－３抗体および組成物
US20240018257A1 (en) Antibodies specific to human poliovirus receptor (pvr)
US11498972B2 (en) Anti-OX40 antibody and use thereof
EP3344658B1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
RU2749109C2 (ru) Специфические антитела к pd-l1 и способы их применения
CN116077647B (zh) 喹啉衍生物与抗体的药物组合
CA3054824A1 (en) Anti-icos agonist antibodies and uses thereof
RS61828B1 (sr) Anti-b7-h3 antitela i antitelske konjugacije lekova
KR20190089949A (ko) 항체 및 이의 사용방법
KR20190035863A (ko) 암 치료를 위한 항Siglec-7 항체
CN115768525A (zh) 用于治疗癌症的组合物和方法
KR20220123105A (ko) 항-갈렉틴-9 항체 및 그것의 용도
CA3223942A1 (en) Anti-ox40 monoclonal antibody and methods of use thereof
JP6964113B2 (ja) がんの処置に使用するための５−ブロモ−２，６−ジ−（１ｈ−ピラゾール−１−イル）ピリミジン−４−アミン
HK1249409A1 (en) 5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer
WO2025228386A1 (en) Anti-entpd2 antibody and use thereof
CN120529917A (zh) 使用抗CTLA4抗体与Pembrolizumab组合治疗癌症的方法
HK40079353A (en) Antibodies specific to human poliovirus receptor (pvr)
HK40089230A (zh) 药物组合物及用途
AU2021330872A1 (en) Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinoma
HK40087544A (zh) 改善与静脉内施用有关的抗体耐受性
HK40044333B (zh) 喹啉衍生物与抗体的药物组合
HK40001896A (en) Antibodies specific to human poliovirus receptor (pvr)
HK40001896B (en) Antibodies specific to human poliovirus receptor (pvr)

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: NOVARTIS A

Effective date: 20210119

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20240807